Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | CTNNB1 |
Variant | N772* |
Impact List | nonsense |
Protein Effect | loss of function - predicted |
Gene Variant Descriptions | CTNNB1 N772* results in a premature truncation of the Ctnnb1 protein at amino acid 772 of 781 (UniProt.org). N772* is predicted to lead to a loss of Ctnnb1 protein function as indicated by reduced transcriptional activity in culture (PMID: 27368802). |
Associated Drug Resistance | |
Category Variants Paths |
CTNNB1 mutant CTNNB1 inact mut CTNNB1 N772* |
Transcript | NM_001098210.2 |
gDNA | chr3:g.41239310_41239312delAATinsTAA |
cDNA | c.2314_2316delAATinsTAA |
Protein | p.N772* |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
XM_017005738.1 | chr3:g.41239310_41239312delAATinsTAA | c.2314_2316delAATinsTAA | p.N772* | RefSeq | GRCh38/hg38 |
XM_024453357.1 | chr3:g.41239310_41239312delAATinsTAA | c.2314_2316delAATinsTAA | p.N772* | RefSeq | GRCh38/hg38 |
XM_024453356.2 | chr3:g.41239310_41239312delAATinsTAA | c.2314_2316delAATinsTAA | p.N772* | RefSeq | GRCh38/hg38 |
XM_017005738.2 | chr3:g.41239310_41239312delAATinsTAA | c.2314_2316delAATinsTAA | p.N772* | RefSeq | GRCh38/hg38 |
XM_047447477.1 | chr3:g.41239310_41239312delAATinsTAA | c.2314_2316delAATinsTAA | p.N772* | RefSeq | GRCh38/hg38 |
NM_001904 | chr3:g.41239310_41239312delAATinsTAA | c.2314_2316delAATinsTAA | p.N772* | RefSeq | GRCh38/hg38 |
NM_001904.4 | chr3:g.41239310_41239312delAATinsTAA | c.2314_2316delAATinsTAA | p.N772* | RefSeq | GRCh38/hg38 |
XM_047447478.1 | chr3:g.41239310_41239312delAATinsTAA | c.2314_2316delAATinsTAA | p.N772* | RefSeq | GRCh38/hg38 |
XM_017005738 | chr3:g.41239310_41239312delAATinsTAA | c.2314_2316delAATinsTAA | p.N772* | RefSeq | GRCh38/hg38 |
NM_001098209 | chr3:g.41239310_41239312delAATinsTAA | c.2314_2316delAATinsTAA | p.N772* | RefSeq | GRCh38/hg38 |
NM_001098210 | chr3:g.41239310_41239312delAATinsTAA | c.2314_2316delAATinsTAA | p.N772* | RefSeq | GRCh38/hg38 |
XM_024453358.1 | chr3:g.41239310_41239312delAATinsTAA | c.2314_2316delAATinsTAA | p.N772* | RefSeq | GRCh38/hg38 |
NM_001098209.2 | chr3:g.41239310_41239312delAATinsTAA | c.2314_2316delAATinsTAA | p.N772* | RefSeq | GRCh38/hg38 |
XM_047447480.1 | chr3:g.41239310_41239312delAATinsTAA | c.2314_2316delAATinsTAA | p.N772* | RefSeq | GRCh38/hg38 |
XM_024453356.1 | chr3:g.41239310_41239312delAATinsTAA | c.2314_2316delAATinsTAA | p.N772* | RefSeq | GRCh38/hg38 |
NM_001098210.1 | chr3:g.41239310_41239312delAATinsTAA | c.2314_2316delAATinsTAA | p.N772* | RefSeq | GRCh38/hg38 |
XM_047447479.1 | chr3:g.41239310_41239312delAATinsTAA | c.2314_2316delAATinsTAA | p.N772* | RefSeq | GRCh38/hg38 |
XM_005264886 | chr3:g.41239310_41239312delAATinsTAA | c.2314_2316delAATinsTAA | p.N772* | RefSeq | GRCh38/hg38 |
NM_001098209.1 | chr3:g.41239310_41239312delAATinsTAA | c.2314_2316delAATinsTAA | p.N772* | RefSeq | GRCh38/hg38 |
NM_001098210.2 | chr3:g.41239310_41239312delAATinsTAA | c.2314_2316delAATinsTAA | p.N772* | RefSeq | GRCh38/hg38 |
NM_001904.3 | chr3:g.41239310_41239312delAATinsTAA | c.2314_2316delAATinsTAA | p.N772* | RefSeq | GRCh38/hg38 |
XM_047447481.1 | chr3:g.41239310_41239312delAATinsTAA | c.2314_2316delAATinsTAA | p.N772* | RefSeq | GRCh38/hg38 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|